Clinical molecular pathology analysis has become an indispensable laboratory tool that can be used to characterise tumour biology and drive therapeutic decisions. Could genetic testing help you get a clear picture of what’s potentially driving tumour growth in your patients?
The potential benefits of routine genetic sequencing in metastatic tumours are recognised by guidelines
Common tests used to detect genetic alterations include both NGS and real-time polymerase chain reaction (PCR)
Test for genetic alterations to ensure you have the information needed to facilitate treatment decision-making
The management of UC is becoming multidisciplinary, with close cooperation and critical input needed from different specialities to provide effective disease management plans for patients
Your pathologist is vital in helping you to tailor your management approach to your patient’s tumour:
When establishing testing protocols, it is important to liaise with the treating urologist to ensure sufficient sample quality is available:
Learn more about FGFR alterations in oncology and their importance in UC: